We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

161 hedge funds and large institutions have $1.56B invested in Revance Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

25% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 44

8% more funds holding

Funds holding: 149 → 161 (+12)

2% more capital invested

Capital invested by funds: $1.53B → $1.56B (+$33.1M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

41% less call options, than puts

Call options by funds: $6.68M | Put options by funds: $11.2M

Holders
161
Holders Change
+12
Holders Change %
+8.05%
% of All Funds
2.8%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
55
Reduced
44
Closed
13
Calls
$6.68M
Puts
$11.2M
Net Calls
-$4.55M
Net Calls Change
-$5.08M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$17.6M
2
Capital World Investors
Capital World Investors
California
+$11.4M
3
PC
Pier Capital
Connecticut
+$4.91M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.32M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$4.09M

Top Sellers

Rank Fund Capital Flow
1
EWM
Essex Woodlands Management
Texas
-$41.1M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$8.17M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$7.66M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.5M
5
FI
Fosun International
China
-$6.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAM
151
Bellevue Asset Management
Washington
$3K -$260 -9 -8%
EW
152
Evoke Wealth
California
$3K – – –
LC
153
Lindbrook Capital
California
$3K – – –
PCG
154
Private Capital Group
Connecticut
$3K – – –
S
155
SignatureFD
Georgia
$2K +$433 +15 +23%
QT
156
Quantbot Technologies
New York
$2K +$2.39K +83 New
AIG
157
American International Group
New York
$1.17K +$76.6K +2,656 +7%
TPCW
158
TD Private Client Wealth
New York
$1.01K – – –
HR
159
Howe & Rusling
New York
$1K – – –
Nisa Investment Advisors
160
Nisa Investment Advisors
Missouri
$90 – – –
Point72 Asset Management
161
Point72 Asset Management
Connecticut
– -$7.5M -268,400 Closed
FI
162
Fosun International
China
– -$6.54M -233,841 Closed
California Public Employees Retirement System
163
California Public Employees Retirement System
California
– -$3.16M -113,060 Closed
EMG
164
ETF Managers Group
New Jersey
– -$945K -33,930 Closed
SCM
165
Soleus Capital Management
Connecticut
– -$870K -31,136 Closed
SC
166
Saltoro Capital
Texas
– -$643K -23,000 Closed
Millennium Management
167
Millennium Management
New York
– -$539K -19,298 Closed
BAM
168
Blueshift Asset Management
New Jersey
– -$440K -15,731 Closed
PA
169
Planning Alternatives
Michigan
– -$326K -11,681 Closed
Simplex Trading
170
Simplex Trading
Illinois
– -$87.9K -3,047 Closed
WAM
171
Wolverine Asset Management
Illinois
– -$47K -1,710 Closed
EVM
172
Eaton Vance Management
Massachusetts
– -$11K -405 Closed
SFS
173
Sowell Financial Services
Arkansas
– -$3K -100 Closed
3 4 5 6
7

RVNC Hedge Fund Activity: Q2 2021 in Review

161 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2021, worth a combined $1.56B — up 2.2% from $1.53B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RVNC positions and 13 closed out — a net gain of 12 holders — while 55 added to existing stakes and 44 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $17.6M. The largest seller was Essex Woodlands Management, cutting an estimated $41.1M.

  • 161 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2021, up from 149 in Q1 2021.
  • Funds reported $1.56B of Revance Therapeutics, Inc. stock for Q2 2021, up 2.2% quarter-over-quarter.
  • 25 funds opened new Revance Therapeutics, Inc. positions in Q2 2021 and 13 closed out, a net change of +12 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q2 2021 was JP Morgan Chase, an estimated $17.6M added.
  • The largest Revance Therapeutics, Inc. seller in Q2 2021 was Essex Woodlands Management, an estimated $41.1M sold.

Based on aggregated 13F filings for Q2 2021.